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Abstract
To meet the challenges of global health, vaccine design and development must be
reconsidered to achieve cost of goods as low as 15¢ per dose. A new recombinant
protein-based rotavirus vaccine candidate derived from non-replicative viral subunits
fused to a P2 tetanus toxoid CD4(+) T cell epitope is currently under clinical develop-
ment. We have sought to simplify the existing manufacturing process to meet these
aims. To this end, we have taken a holistic process development approach to reduce
process complexity and costs while producing a product with the required character-
istics. We have changed expression system from Escherichia coli to Pichia pastoris, to
produce a secreted product, thereby reducing the number of purification steps. How-
ever, the presence of proteases poses challenges to product quality. To understand
the effect of fermentation parameters on product quality small-scale fermentations
were carried out. Media pH and fermentation duration had the greatest impact on
the proportion of full-length product. A novel acidic pH pulse strategy was used to
minimize proteolysis, and this combined with an early harvest time significantly
increased the proportion of full-length material (60–75%). An improved downstream
process using a combination of CIEX and AIEX to further reduce proteases, resulted
in maintaining product quality (95% yield).
K E YWORD S
fed-batch fermentation, ion exchange chromatography, Pichia pastoris, proteolysis, vaccine
development
1 | INTRODUCTION
The Ultra Low-cost Transferable Automated (ULTRA) Platform for
Vaccine Manufacturing seeks to combine integrated, automated, mod-
ular manufacturing1 to achieve the aims of the Bill & Melinda Gates
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Foundation Grand Challenge—“Innovations in Vaccine Manufacturing
for Global Markets”. The stated aim of which is “to create a new
manufacturing platform to enable ultra-low cost, high quality, recom-
binant subunit vaccines at 15¢ (USD) a dose for global health initia-
tives.” Our initial model system to demonstrate this approach is the
production of a recombinant subunit rotavirus vaccine candidate.
Rotaviruses are one of the most common causes of severe diarrheal
disease, which prior to the introduction of an effective vaccination pro-
gram was estimated to result in 500,000 deaths in infants and children
worldwide annually.2 This was found to be reduced to around 200,000
deaths annually in 2013 following introduction of vaccination programs,
with the majority of these occurring in low-income countries.3 Cur-
rently, there are two oral live virus rotavirus vaccines available, Rotarix®
(GlaxoSmithKline) and RotaTeq® (Merck) both of which are rec-
ommended for inclusion in routine childhood vaccination programs by
the World Health Organisation.4 Recently, two further vaccines,
Rotasil® (Serum Institute of India) and ROTAVAC® (Bharat Biotech),
have also been pre-qualified for use by the WHO. However, the effi-
cacy of these vaccines has been found to be low in some low-income
countries with the highest need.5 Other concerns with the use of these
oral live virus vaccines include an association with a risk of intussuscep-
tion6 and a potential for re-assortment of live vaccine stains with circu-
lating wild-type virus stains.7 In addition, the cost of these vaccines is
relatively high and is further increased by the requirement for an exten-
sive cold chain during storage and distribution.8 To alleviate these
issues, new Non Replicative Rotavirus Vaccine (NRRV) based on the
VP8 viral proteins from the P[4], P[6], and P[8] serotypes, fused to the
P2 universal tetanus toxoid CD4(+) T cell epitope, have been developed
and are currently undergoing clinical trials.9,10
Currently, these NRRV antigens are expressed intracellularly in
Escherichia coli, with subsequent purification, requiring three chroma-
tography steps (Figure 1a).9 Our aim is to move to a secreted system
to significantly simplify this process, ultimately to be capable of incor-
poration into a single integrated process (Figure 1b),1 thereby reduc-
ing cost towards meeting the target of 15¢ per dose or less.
To simplify the production and purification process of NRRV, Pichia
pastoris, a methylotrophic yeast, was used as expression system as it
provides several advantages over E. coli. For example, P. pastoris can
achieve high cell densities in fermentation, and it is capable of secreting
high titers of correctly folded heterologous protein.11,12 In addition, the
secretion of endogenous proteins is very low, which is advantageous
for the simplification of downstream processing (DSP).13,14
One potential drawback of using P. pastoris as an expression sys-
tem for heterologous proteins is the presence of proteolytic
enzymes.15,16 These can have detrimental effects, such as product
degradation or truncation, leading to reduced yield, and loss of biologi-
cal activity.15,17,18 Several approaches have been used to minimize the
damage caused by proteolytic activity. At a fermentation level, supple-
mentation with casamino acids and yeast peptone (substrate
competition),18 addition of protease inhibitors,19,20 changes in fermen-
tation parameters such as reduction of pH and temperature,12,15,21,22
as well as utilization of alternate carbon sources, and optimization of
induction times have all been used to reduce proteolytic degrada-
tion.17 However, a generalized approach to solving problems of
proteolytic degradation has not been established and solutions are
case-by-case. Any actions taken at an upstream level to mitigate
proteolysis, such as addition of inhibitors or competitors, can have
consequences for the subsequent downstream, which will have to be
capable of removing any additional components or inhibitors.23 The
introduction of changes to an already defined antigen designed to
decrease susceptibility to proteolysis can have regulatory conse-
quences.24 Therefore, the development of upstream processing (USP)
conditions that result in minimal protease activity are of great impor-
tance in production of full-length products.
In this study, a whole process approach was taken to identify
compatible upstream and downstream conditions, where product
quality was improved in fermentation and maintained throughout the
purification process, to produce the highest proportion of full-length
NRRV (Figure 2).
2 | MATERIALS AND METHODS
Chemicals, unless specified otherwise, were obtained from Sigma
Chemical Co. Ltd. (Poole, Dorset, UK).
2.1 | Cells and seed cultures
Fermentations were performed with Pichia pastoris (Komagataella
phaffii NRRL Y-11430) secreting a P[4] or a P[8] serotype of a non-
replicating rotavirus VP8-derived subunit vaccine under control of the
F IGURE 1 Schematic process for the production of NRRV
expressed in E. coli and P. pastoris. NRRV production process (a) from
product expressed in E. coli9 and (b) P. pastoris process in fed-batch or
perfusion mode with 1 or 2 stage chromatography
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AOX1 promoter (a gift from the Love Lab at the Koch Institute at
MIT) were re-streaked from a frozen clonal stock onto solid yeast
extract peptone dextrose media. A single colony was picked and
expanded in buffered glycerol complex medium (BMGY) to create
working cell banks (WCW).
Inocula from WCW were grown in BMGY medium incubated at
30C for fermentations in Basal Salt Medium (BSM)25 or 25C for fer-
mentations in Rich Defined Medium (RDM),26 250 rpm until they
reached an OD600 ~10.
2.2 | Fed-batch fermentation
Fermentations were carried out using an ambr® 250 modular micro-
bial system (Sartorius Stedim Biotech, Royston, UK). The bioreactors
and integral reservoirs were aseptically filled with sterile media and
feed solutions. Fermentations were carried out following Invitrogen's
protocol for Mut+ cells.25 The initial fermentation volume was 120 mL
of BSM with 0.52 mL of PTM1 trace salts. The operating conditions
were 30C, 30% DO (using air or a mix of air and oxygen when
required at 0.5 vvm), pH 5.00 ± 0.15 (controlled with 10% [v/v]
ammonium hydroxide), and antifoam (polypropylene glycol 2000) was
automatically added by the system when required. Reactors were
inoculated via the septum to an OD600 of 1.
Measurements from off-gas CO2 sensors in the ambr250 modular
were used by the system to calculate the carbon evolution rate (CER).
A 20% drop in CER was used to detect the end of batch phase and
automatically started the glycerol feed (18.15 mL/hr per liter of the
initial fermentation volume [Li Vol]). Followed by a methanol
adaptation phase using feed rate of 3.6 mL/hr/Li Vol. A decrease in
CER during methanol adaptation indicated depletion of glycerol and
was used as signal by the system to increase methanol feed rate, using
an incremental step profile programmed into the ambr250 software
(7.3 mL/hr/Li Vol for 2 hr and 10.9 mL/hr/Li Vol for the remainder of
the fermentation). Glycerol and methanol feed rates were those speci-
fied by Invitrogen's protocol for Mut+ cells grown at 30C.25
At the end of fermentation, the cell broth was centrifuged at 10,000
× g for 15 min and the supernatant was filtered using 0.80 μm cellulose
nitrate and 0.45 μm polyvinylidene difluoride membrane filters
(GE Healthcare Life Sciences, Buckinghamshire, UK). Samples were
aliquoted into 20 or 30 mL and stored at −20C until further processing.
2.3 | Fermentation optimization
Fermentation parameters for batch and glycerol fed-batch phases for
BSM (30C, 30% DO, pH 5.00 ± 0.15) and RDM (25C, 25% DO,
pH 6.50 ± 0.15) remain constant throughout the different fermentations,
except for the fermentations listed in Figure 3a where the pH was chan-
ged (RDM 9 & 10). The pH was controlled with 10% (v/v) ammonium
hydroxide, except for fermentations RDM 1 (Figure 3a) where it was
controlled with potassium hydroxide solution (5 M) and RDM 2 with
KOH during batch phase and NH4OH during fed-batch phase.
The pH shift (Figure 3b, RDM 11 & 12) and early pH pulse
(Figure 3b, RDM 15–18) were implemented at the end of methanol
adaptation (~30 hr), and late pH pulse was implemented ~60 hr
(Figure 3b, BSM 3–5, RDM 13 & 14). The reduction of the pH set
point was achieved by turning off addition of base until the new pH
F IGURE 2 Schematic representation of NRRV (non-replicating rotavirus VP8-derived subunit vaccine) and its sequence with the
corresponding intact mass spectrometry data. (a) Schematic representation of P2-VP8-P[4]. (b) Sequence for full-length P2-VP8-P[4] and
(c) different N-terminal truncated species. Intact mass spectrometry data from fermentation samples of P. pastoris P[4], data edited to illustrate:
(d) full-length P2-VP8-P[4] and (e) different N-terminal truncated species
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set point was reached (~2 hr), held at pH 3.00 ± 0.15 for ~4 hr and
then ramped for an hour to the higher set point using a programed
function of the ambr250 software.
Induction temperature was reduced at the end of glycerol fed-
batch (Figure 3a and b, BSM 2, RDM 10, 12, 17, 18).
RDM 11 and 12 were supplemented throughout methanol
adaptation and induction with amino acids (L-glutamine, L-arginine,
and L-asparagine) to a final concentration of 1 mM.
Supplementation of protease inhibitor (aprotinin) (Figure 3a RDM 7) or
casamino acids (Figure 3a RDM 8) was done at the end of glycerol fed-batch
(~25 hr) to a final concentration of 3.9 μg/mL and 1% (v/v), respectively.18
For fermentations in BSM and RDM at 25C methanol feed rate
was 7.60 mL/hr/Li Vol which corresponds to 70% of the methanol
feed rate recommended in Invitrogen's protocol for Mut+ cells grown
at 30C,25 based on previous experience. Residual methanol concen-
tration in the supernatant was measured off-line (M&M Section 2.10).
Methanol adaptation was done in incremental steps programed into the
ambr250 software as follows: 1.16 mL/hr/Li Vol for 4–5 hr until CER
decreased (M&M Section 2.2) subsequently 2 hr steps of 2.0, 4.8, and
5.60 mL/hr/Li Vol. When induction temperature was reduced methanol
feed rate was changed to 7.20 mL/hr/Li Vol for BSM at 20C (BSM 2),
5.30 mL/hr/Li Vol for RDM at 20C (RDM 12 & 17), and 3.75 mL/hr/Li
Vol for RDM at 15C (RDM 10 & 18). Methanol adaptation feed rates
were reduced by 30% for 20C and 50% for 15C.
2.4 | Chromatography: resin selection
To assess the suitability of resins for use in bind, elute chromatography
as the first stage in the purification process automated micro-scale
chromatography was carried out on a TECAN Evo liquid handling plat-
form (Tecan UK Ltd, Reading, UK), using 96 well filter plates with either
F IGURE 3 Fed-batch fermentation parameters tested for P. pastoris expressing a NRRV. Proportion of full-length P2-VP8-P[4] and truncated
species determined by intact mass spectrometry and dry cell weight (DCW) at two different time points post-inoculation. (a) Fermentations
carried out at the indicated pH, (b) fermentations carried out with a pH pulse or pH shift, (c) scale for P2-VP8-P[4] concentration, the area of the
circle showing full-length and truncated P2-VP8-P[4] species (a and b) is proportional to its concentration in the supernatant
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2 or 20 μL per well (GE Healthcare Life Sciences)27 or 0.6 mL RoboColumns
(custom packed by Repligen Europe B.V, Breda, The Netherlands).28 A total
of 18 resins were screened for binding capacity and product quality
(Table 1), determined by SDS-PAGE. Resins from the following functional
classes were screened: hydrophobic interaction (HIC), cation exchange
(CIEX), and multimodal cation exchange (MM). HIC resins were screened for
binding and elution at pH 4.0 and pH 7.5, over an ammonium sulfate con-
centration range of 0–1 M. CIEX and MM resins were screened over a pH
range of 3.0–7.5 and a NaCl concentration of 0–1 M. Clarified fermentation
medium was buffer exchanged for the appropriated binding buffer by dia-
filtration at 4C using a 3 kDa cutoff regenerated cellulose membrane
(Amicon Ultra 15, Merck Millipore, Watford, UK). Clarified medium was
repeatedly diluted threefold and re-concentrated to original volume. This
was repeated six times until the buffer exchange was >99.5%. The best per-
forming resin from each class was then scaled-up.
2.5 | Hydrophobic interaction chromatography
HIC chromatography was performed on a 1 mL HiTrap Capto Phenyl
(High Sub) column (GE Healthcare Life Sciences) at 1 mL/min attached
to an AKTA Avant system (GE Healthcare Life Sciences). Purification
was carried out in a base buffer of 50 mM Tris, pH 7.5 or 50 mM
sodium citrate, pH 4.0. Clarified fermentation medium was buffer
exchanged at 4C using a 3 kDa cutoff regenerated cellulose mem-
brane as in Section 2.4 into the appropriate pH buffer. This was
brought to a final (NH4)2SO4 concentration of 1 M by addition of a
3 M (NH4)2SO4 in buffer stock solution. Bound protein was eluted by
step-wise decreases in (NH4)2SO4 concentration.
2.6 | Multimodal chromatography
MMC was performed on 1 mL Nuvia cPrime columns (Bio-Rad Ltd,
Hertfordshire, UK) at 0.5 mL/min. Binding was carried out at pH 4.0
in 50 mM sodium citrate buffer. P2-VP8-P[4] was eluted at pH 6.0 in
50 mM sodium citrate buffer.
2.7 | Cation exchange chromatography
CIEX chromatography was performed on 1 and 5 mL HiTrap Capto S
ImpAct columns (GE Healthcare Life Sciences) at 1 or 5 mL/min on
the AKTA Avant. Binding was carried out at pH 4.0 in 50 mM sodium
citrate buffer. In initial experiments a gradient of 0–1 M NaCl in bind-
ing buffer was used as elution. However, to facilitate subsequent
processing by AIEX without the need for a buffer exchange, a pH step
to pH 7.5 in 50 mM Tris buffer was used to specifically elute
P2-VP8-P[4].
2.8 | Combined cation and anion exchange
chromatography
A two-step chromatography procedure was used for routine purifica-
tion of all NRRV products. This was developed to maximize product
purity and quality while minimizing the requirements for buffer
exchange and thus ease of incorporation into a future integrated pro-
duction system.
Clarified fermentation medium was brought to pH 4.0 by addi-
tion of 0.1 M citric acid. Conductivity was then adjusted to
10 mS/cm by addition of 50 mM sodium citrate, pH 4.0 buffer. This
allowed for direct binding onto the Capto S ImpAct column. HCP
were removed by a wash of 0.2 M NaCl in 50 mM sodium citrate,
pH 4.0. Following removal of NaCl, a step of 50 mM Tris, pH 7.5
was employed to elute P2-VP8-P[4]. This eluate was then applied
directly to a 5 mL HiTrap Capto Q ImpRes column (GE Healthcare
Life Sciences) pre-equilibrated in 50 mM Tris, pH 7.5. P2-VP8-P
[4] was recovered in the flow-through, with remaining HCP and
DNA binding to the column.
TABLE 1 Affinity resins screened for potential first bind-elute chromatography step
Resin class—HICa Resin class—CIEX Resin class—MM
Resin
Relative static
binding capacity Resin
Relative static
binding capacity Resin
Relative static
binding capacity
Capto phenyl (high sub)b 1.00 Capto S ImpAct 1.00 Nuvia cPrime 1.00
Phenyl Sepharose 6 FF (low sub) 0.64 Capto Sc 0.90 Capto MMC 0.32
Capto butyl 0.93 SP Sepharose FF 0.40 Capto MMC ImpRes 0.32
Phenyl Sepharose 6 FF (high sub) 1.10 Capto SP ImpRes 1.00 PPA Hypercel 0.30
Butyl-S Sepharose 6 FF 0.46 Toyopearl MX-Trp-650 M 0.30
Octyl Sepharose 4 FF 0.89 CMM Hypercel 0.85
Butyl Sepharose 4 FF 0.66
Capto Octyl 0.56
aResins from the following functional classes were screened; hydrophobic interaction (HIC), cation exchange (CIEX), and multimodal cation exchange (MM).
bThe best performing resin from each class is indicated in bold.
cResins shown italicized had adequate binding capacity but significant product truncation occurred during purification as determined by SDS-PAGE
and MS.
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2.9 | Intact mass analysis of fermentation and
purified NRRV samples
Before intact mass analysis, all NRRV fermentation samples were
freshly thawed and buffer exchanged three-times at 4C to PBS
buffer pH 7.2 using Amicon™ Ultra-4, 10 kDa MWCO centrifugal fil-
ters (EMD Millipore) to remove fermentation media. Both purified and
buffer-exchanged fermentation samples were centrifuged at
14,000 × g for 1 min, and the top ~80% of the centrifuged protein
sample was transferred to an HPLC vial. Intact mass analysis was per-
formed using a 1220 LC system (Agilent Technologies, CA) connected
in-line to a 6230B time-of-flight mass spectrometer (Agilent Tech-
nologies) with typical injection volumes consisting of 0.5–5 μL
(~15–20 pmol). Fermentation and purified protein samples were
desalted using BEH C4 guard column, 2.1 × 5 mm, 1.7 μm (Waters
Corporation, MA) and ZORBAX 300SB C3 column (Agilent Tech-
nologies), respectively. The LC gradient consisted of 20–90% B (A:
water + 0.1% formic acid, B: acetonitrile + 0.1% formic acid) over
2 min at a flow rate of 0.8 mL/min for fermentation samples, and
20–70% B over 1 min at a flow rate of 1.5 mL/min for purified
samples. Elution of NRRV proteins was monitored using the absor-
bance signal at 214 nm. One hundred microliters of isopropanol
was injected after each sample to minimize carryover effect. The
typical electrospray ionization parameters consisted of: 290C gas
temperature, 4,000 V Vcap, and 275 V fragmentor. Mass spectra
were collected from 700 to 2,800 m/z at 1 spectra/sec. Mass spec-
tra were processed using MassHunter (Agilent Technologies), and
the deconvolution range consisted of 10–50 kDa, with 1 Da
mass step.
2.10 | Analytical methods
Cell growth was measured off-line using optical density measure-
ments at 600 nm, wet, and dry cell weight (WCW, DCW).
Concentrations of glycerol and methanol in fermentation super-
natant were determined off-line using a Dionex UltiMate 3000 ultra-
high performance liquid chromatography with refractive index
detector (Thermo Scientific, Loughborough, UK) with Aminex HPX-
87H column (Bio-Rad, Hertfordshire, UK).
Protein concentration from culture supernatant and purification
fractions was quantified using BCA assay (23225 Pierce™ Thermo
Fisher Scientific, Loughborough, UK) and SDS-PAGE 12% Bis-Tris
protein mini gels as per manufacturer's instructions (NuPAGE™,
Thermo Fisher Scientific) using MOPS as running buffer. The propor-
tion of heterologous proteins was determined by densitometry using
Image Quant software (GE Healthcare Life Sciences).
Proteases in fermentation and purified samples were detected using
Novex™ 10% Zymogram plus protein gels with gelatin (Thermo Fisher
Scientific) as per manufacturer's instructions (incubating at 37C, 24 hr).
Host cell protein (HCP) concentration of purified samples was
determined using P. pastoris HCP ELISA kit (F140 Cygnus, Southport,
NC) as per manufacturer's instructions. Values were calculated from
three sample dilutions and expressed as parts-per-million (ppm). The
cut-off level for acceptable purity was set at a HCP level of 500 ppm.
DNA concentration of purified samples was determined using a
Quant-iT dsDNA high sensitivity assay kit (Thermo Fisher Scientific)
as per manufacturer's instructions. For comparative purposes, DNA
contamination levels in purified product is expressed as ng or pg DNA
per dose, using the highest dose amount of 60 μg, currently under
clinical evaluation.9,10
3 | RESULTS AND DISCUSSION
3.1 | Identification of product truncation during
fermentation
A NRRV subunit vaccine was expressed in P. pastoris using an α-mating
factor secretion signal, resulting in the protein of interest being secreted
from the cells. Molecules of 20,517 and 20,386 Da were both considered
as full-length P2-VP8-P[4], as the methionine (131 Da) on the N-terminal
was an artifact of cloning from E. coli to P. pastoris (Figure 2b and d).
Truncated species of P2-VP8-P[4] were defined when any other amino
acid residues of the N-terminal end were missing (Figure 2c and e).
Following Invitrogen's protocol, cells were grown in fed-batch
mode and induced with methanol.25 WCW achieved in fermentation
BSM 1 was within the range expected (101 g/L);25 however, intact
mass spectrometry analysis showed that there were mainly N-terminal
truncated species (Figure 3a). Reduction of induction temperature is
known to improve yields of recombinant proteins; in this case, the
induction temperature was reduced from 30 to 20C (BSM 2), this did
not impact the protein yield, and only a small proportion of full-length
P2-VP8-P[4] was observed at the two time points analyzed.
The tetanus toxoid P2 epitope has been shown to improve the
immunogenicity of VP8 proteins (Figure 2a), and truncations of the P2
region could potentially lead to lower efficacy.29 To reduce the proportion
of N-terminal P[4] truncated species, we investigated the fermentation
parameters (medium, pH, temperature, and harvest point) and purification
sequence to produce full-length P2-VP8-P[4] (Figure 2a and b).
3.2 | Impact of media and pH control
Initial fermentations were carried out using a rich defined media (RDM),
and pH was controlled with potassium hydroxide (Figure 3a, [RDM 1]).26
Cell growth and protein production were lower than in BSM 1 and
2, which could have been caused by nitrogen limitation.30 Despite the
low titer (0.55 g/L), product quality was much improved to 55% full-
length P2-VP8-P[4] at 46 hr; however, it was not stable over time,
decreasing to 20% at 76 hr. Ammonium hydroxide was used to control
pH either during induction (RDM 2) or throughout the whole fermenta-
tion (RDM 3 & 5).31 Both strategies proved to be an efficient way to
overcome the limitations in cell growth and protein production observed
in RDM 1. To ease bioreactor operation, NH4OH was used to control pH
throughout the whole fermentation in all further experiments. In changing
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pH from 6.5 to 7.0 (RDM 3) again, approximately 55% full-length
P2-VP8-P[4] was observed at 46 hr; however, this was not stable, and by
76 hr, P2-VP8-P[4] was fully truncated.
3.3 | Identification of product truncation
It is known that proteases can be problematic during the production of
heterologous proteins in P. pastoris.17,18 To verify if proteases were the
cause of product truncation over culture time, two approaches were
taken: addition of protease inhibitor (aprotinin [RDM 7])19,20 or sub-
strate competition (casamino acids [RDM 8]).18 Both strategies were
successful, and at harvest (77 and 63 hr, respectively), the proportion of
full-length P2-VP8-P[4] was ~40%. However, the use of protease inhibi-
tors can be detrimental for cell growth, costly when scaling up, and have
regulatory challenges.23 Supplementation of casamino acids can be chal-
lenging for USP and DSP, due to the variability in composition and the
introduction of complex components (animal origin) to defined media.30
For these reasons, we chose not to modify the media but focus on USP
control strategies to inhibit protease activity.
3.4 | pH and temperature to control product
truncation
Reduction of pH and temperature during fermentation have been used
to decrease protease activity in fermentation supernatant.12,15,21,22
Therefore, we tested these strategies to reduce protease activity and
therefore product truncation to improve product quality.
Low pH strategies were tested: pH 4.0 throughout the fermenta-
tion (RDM 9 & 10) or a pH reduction strategy during induction from
pH 6.5 to pH 3.0 (RDM 11& 12) with amino acid supplementation to
avoid nitrogen limitation.26 Fermentations carried at pH 4.0 (RDM 9 &
10) showed ~10% full-length P2-VP8-P[4] at harvest (70 hr). Fermenta-
tions with pH shift (RDM 11) showed ~30% full-length P2-VP8-P[4] at
51 hr, and this proportion remain constant until harvest (70 hr).
Both low pH strategies were at carried out at 25C or with a temper-
ature reduction during induction (25! 15C [RDM 10] and 25! 20C
[RDM 12]). In both cases, reducing induction temperature did not increase
the proportion of full-length P2-VP8-P[4]; on the contrary, when
temperature was reduced to 15C, the proportion of full-length
decreased to 15% (RDM 18). In our case, reducing pH during metha-
nol induction was observed to be a favorable strategy to lower pro-
teolytic activity and thereby increasing the proportion of full-length
P2-VP8-P[4].12,21 However, further improvement was necessary to
increase this proportion. Therefore, a novel strategy was designed
where pH was reduced over a period of time by utilizing cell metabo-
lism acidification when stopping the addition of base. The pH was
held low for 1–3 hr and then increased to the original set point (BSM
3–5 and RDM 13–18). Under certain circumstances, this proved to
be a successful strategy; for fermentation RDM 15 at 46 hr, 75%
full-length was observed; however by 77 hr, the proportion of full-
length P2-VP8-P[4] decreased to 20% (Figure 3b).
A reduction of temperature in combination with a pH pulse was
tested in an attempt to maintain the highest proportion of full-length
P2-VP8-P[4]. However, reducing induction temperature did not improve
product quality (RDM 17 & 18) (Figure 3b). When induction temperature
was reduced to 15C, due to low cell metabolism fermentation, the pH
only reached 5 instead of 3. The pH pulse strategy was also tested with
BSM (BSM 3) where 60% of the product was full-length P2-VP8-P
[4] (Figure 3b), which was a significant improvement on fermentation
BSM 1 where only truncated species were present (Figure 3a).
Zymograms were used to detect the presence of proteolytic
enzymes in the fermentation supernatant throughout methanol induc-
tion (RDM 12) (Figure 4a). Protease activity at ~60 and ~40 kDa were
visible at 37 and 39 hr when pH was greater than 6.1. When pH was
reduced to 3.4, proteolytic activity was reduced and was neither detect-
able in the zymogram nor when the pH was increased to 6.4 (45 to
47 hr). Suggesting that a decrease on pH during methanol induction
was an efficient strategy to reduce proteolytic activity in fermentation
supernatant.
Based on these findings, a pH pulse during methanol induction
was proposed and tested with BSM and RDM, leading to 60 and 75%
full-length P2-VP8-P[4], respectively (Figure 3b). However, depending
on the media used, the reduction in pH was conducted at different
times during the fermentation, at 60 and 30 hr for BSM and RDM,
respectively (BSM 4 & 5 and RDM 15; Figure 3b).
3.5 | Effect of fermentation time on product
truncation
For most of the conditions tested, it was found that of the variables
tested fermentation time had the greatest impact on product quality,
as the proportion of truncated species increased overtime.17 For
example, for RDM 15 (Figure 3b), P2-VP8-P[4] concentration at 46 hr
was 1.7 g/L of which 75% is full-length (1.25 g/L), and at 77 hr, pro-
tein production increased to 4.8 g/L but only 20% was full-length
(0.96 g/L), showing that longer induction was not beneficial. There-
fore, an early harvest point was chosen where a greater proportion of
full-length protein was present in the supernatant, as the presence of
closely related product impurities in harvest material would likely be
challenging for DSP.
In the cases where the pH pulse was carried out, there was a
short window to harvest before the product becomes truncated, this
was approximately 3 hr after pH reached the upper set point; longer
induction times lead to loss in full-length P2-VP8-P[4] as seen in RDM
15. Alternative to avoid product truncation after holding pH at the
high set point for 3 hr, temperature was reduce to 6C, pH 4.0 and
held low overnight. This was tested with P2-VP8-P[8], and the pro-
portion of full-length P2-VP8-P[8] was similar to when harvested 3 hr
after the end of pH pulse, data not shown.
From all the conditions tested, three fermentation strategies led to
the highest proportion of full-length P2-VP8-P[4]. These were: (A) RDM
at pH 6.5 or 7.0, harvest at 47 hr (RDM 4 & 6, respectively), (B) RDM
with pH pulse (~30 hr) and harvest at 47 hr (RDM 16), and (C) BSM
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with pH pulse (~60 hr) and harvest at 70 hr (BSM 3) (Figure 3b). The
purification of P2-VP8-P[4] produced by these three fed-batch fermen-
tation strategies presented different challenges to DSP.
3.6 | Resin screening
We aimed to use a rational design approach to the development of
DSP protocols, leading to the simplest process possible, ultimately
being capable of incorporation into an integrated process
(Figure 1b).1 To this end, combinations of chromatography elements
were designed in such a way as to eliminate any intermediate buffer
exchanges.
To select the best performing matrix for P2-VP8-P[4] purification, a
total of 18 resins were tested in a combination of static binding and
dynamic binding studies using automated 96-well filter plate assays27
and 0.6 mL RoboColumns28 (Table 1). Resins were tested to define opti-
mal binding and elution conditions for both pH and ionic strength. Resin
suitability was also determined by product quality using SDS-PAGE to
assess the level of truncation during the purification. The best performing
resin from each of the classes tested were then scaled up to 1 and 5 mL
columns for further optimization. These were: HIC – Capto Phenyl (High
Sub); multimodal – Nuvia C Prime; cation exchange – Capto S ImpAct.
3.7 | Hydrophobic interaction chromatography
HIC is used as a bind-elute step in the published protocol based on
E. coli expressed material, after the removal of HCP by anion exchange.9
Therefore, it was expected that yeast expressed P2-VP8-P[4] could be
purified by a bind-elute strategy using HIC resins. This was indeed the
case. However, to obtain efficient binding, the clarified medium must
first be subject to buffer exchange and addition of 1 M ammonium sul-
fate. P2-VP8-P[4] is eluted by decreasing the ammonium sulfate con-
centration to 0.8 M (Figure 5a). Initially, clarified medium was buffer
exchanged to Tris at pH 7.5 (pre-treatment A, Figure 5a) as this was the
binding condition shown to work for bacterial P2-VP8-P[4]. However,
as shown in Figure 5a, bringing the pH to 7.5 leads to a high level of
truncation of P2-VP8-P[4] by residual protease activity. This could
decrease the yield of full-length protein due to proteolysis during han-
dling/purification. To alleviate this, clarified medium was instead buffer
exchanged to a pH of 4.0 (pre-treatment B, Figure 5a). This was found
not to change the bind-elute characteristics of P2-VP8-P[4] (Figure 6a).
However, performing the chromatography at this reduced pH did not
have the desired effect of reducing protease activity during purification,
rather it resulted in a higher levels of truncation compared to P2-VP8-P
[4] after HIC purification at pH 7.5 (Figures 5a and 6a). Use of HIC
alone also resulted in unacceptably high levels of both HCP
(>1,000 ppm) and residual DNA (16–24 ng/dose) irrespective of chro-
matography pH (Figure 5a). Although this protocol produced full-length
material, it was not stable to further proteolysis, becoming completely
truncated within 4 days at room temperature. Showing that significant
levels of protease remained after HIC purification (data not shown).
3.8 | Cation exchange and multimodal
chromatography
The HIC procedure while being significantly simplified over that used
previously is still too complex for incorporation into a fully integrated
process,1 due to the requirement for buffer exchanges. Ideally, a pro-
cess that requires no buffer exchange to be performed between the
steps is desirable. This situation is most easily met by the use of a cat-
ion exchange or multimodal resin as the capture step. Examples of both
classes of resin were found to be able to purify P2-VP8-P[4] (Table 1).
However, the use of a cation exchanger (Capto S ImpAct) was found to
provide the most robust protocol. To achieve efficient binding, it is suf-
ficient simply to adjust the clarified medium to pH 4.0 and conductivity
to 10 mS/cm by direct addition of dilute citric acid (pre-treatment D,
Figure 5b). This removes the need for any buffer exchange between
fermentation output and column purification, thereby increasing
F IGURE 4 Zymograms from supernatant of P. pastoris
fermentation and purified samples. (a) Samples from fermentation
supernatant of P2-VP8-P[4] in RDMwith pH pulse (RDM 16) from
6.5! 3.0! 6.5 between 38 and 45 hr. (b) Fermentation harvest after
a freeze thaw cycle (USP 47 hr); after pH adjustment to pH 4 (pH) and
conductivity (Cond); CIEX samples flow through (F), 0.2 M NaCl wash
(W), and pH 7.5 elution/AIEX input (E) and AIEX flow through (F).
Positive controls: thermolysin (37 kDa) and trypsin (19 kDa)
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compatibility with an integrated USP-DSP process.1 The residual prote-
ase, which also binds the column, is efficiently removed by a pre-elution
wash step at pH 4.0 with 0.2 M NaCl (Figure 4b). P2-VP8-P[4] is then
eluted by increasing the salt to 0.4 M NaCl. The material produced by
this single-column purification was found still to contain residual prote-
ase activity, which was only detected by MS analysis of material stored
F IGURE 5 Downstream processing
and purification of NRRV from best
performing fed-batch fermentations.
Proportion of full-length P2-VP8-P[4] and
truncated species determined by intact
mass spectrometry. Required pre-column
treatment is shown and bind-elution
conditions indicated. Product recovery
was determined by mass balance
calculation using densitometry of SDS-
PAGE. HCP and DNA content were
determined for final purified NRRV (using
the highest dose amount of 60 μg,
currently under clinical evaluation).
(a) One-stage chromatography by HIC.
(b) Two-stage chromatography by CIEX
followed by AIEX. For cases were
insufficient levels of full-length, NRRV
was recovered after initial CIEX step no
further processing was performed
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at room temperature for 2 days. This revealed that further truncated
species were being formed. To remove this activity and other residual
HCP and nucleic acid impurities, a second anion exchange column
(Capto Q ImpRes) was included in flow through mode (Figure 5b). This
resulted in final HCP levels of <500 ppm and residual DNA of 26 pg/
dose. To alleviate the need for a buffer exchange between cation and
anion exchange columns, the elution procedure was modified such that
following the pH 4.0, 0.2 M NaCl wash the column is brought back to
0 M NaCl. P2-VP8-P[4] is then eluted by elevating the pH to 7.5
(Figures 5b and 6b). This eluate is then applied directly to a Capto Q
ImpRes column, where the HCPs and DNA are bound and the
P2-VP8-P[4] is in the flow-through (Figures 5b and 6b). This simplified
protocol also resulted in final HCP levels <500 ppm and DNA levels of
30 pg/dose (Figure 5b) and is compatible with incorporation into an
integrated USP–DSP methodology.1 Material produced in this manner
was found to be stable at pH 7.5 for up to 8 days at room temperature
when analyzed by intact MS (data not shown).
3.9 | USP-DSP interactions
Having significantly improved the individual elements of both USP and
DSP a whole process approach was used to identify the best integrated
process to give the highest yield of full-length P2-VP8-P[4] (Figure 7a).
Irrespective of fermentation medium (BSM or RDM), the use of a pH
pulse was required to produce high titers of P2-VP8-P[4] with the
majority being full-length (Figure 7a, [BSM 3, RDM 16]). However mate-
rial generated using BSM must first undergo a buffer exchange to allow
processing on a CIEX, this results in a 50% loss of P2-VP8-P[4] through
the entire DSP (Figure 5b [BSM 3 & 5]). BSM fermentations at 25C
F IGURE 6 SDS-PAGE analysis of
downstream processing and purification
of NRRV serotype P[4] from fed-batch
fermentation (RDM 16). Pre-treatment
and bind-elute conditions are as defined
in Figure 5. Input indicates material post
pretreatment. The percentage of
P2-VP8-P[4] was calculated by
densitometry and the OD260/280 ratios
measured directly from the column
fractions. (a) One stage HIC
chromatography at pH 7.5 (pre-treatment
A) and pH 4.0 (pre-treatment B). (b) Two-
stage CIEX–AIEX chromatography from
material using pre-treatment D (pre-
treatment C gave identical results)
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(BSM 5) and 30C (BSM 3) both produce acceptable levels of full-length
P2-VP8-P[4]. However, when the material produced at 30C is
processed through a DSP, the resulting product is almost entirely trun-
cated, with less than 10% full-length, after buffer exchange and CIEX
chromatography. This is not the case for material grown at 25C which
resulted in a final product being ~60% full-length, after buffer exchange
and both CIEX and AIEX chromatography. This most likely indicates
higher levels of protease at the higher temperature (Figure 5b).
The use of RDM in fermentation removes the need for a buffer
exchange before DSP. To produce a high titer of full-length P2-VP8-P[4],
fermentations require a pH pulse and a short induction period. The har-
vest only requires adjustment of pH and conductivity to allow it to be
passed rapidly through the CIEX–AIEX chromatography. Maintaining 72%
of full-length P2-VP8-P[4] with a 95% recovery over the whole process.
3.10 | Verification of the improved process
The improved fermentation protocol RDM 15 (RDM, 25C,
pH 6.5! 3.0! 6.5, harvest 3 hr after end of pH pulse [~47 hr])
(Figure 7a) was tested with P2-VP8-P[4] (RDM 16). At harvest, DCW
was 63 ± 2.3 g/L, protein concentration of 2.17 ± 0.16 g/L (n = 4),
and 60% of full-length P2-VP8-P[4] (Figure 7b). The corresponding
CIEX and AIEX (pre-treatment D, Figure 5b) purified material had 72%
full-length product (Figure 7a).
There was a difference in the percentage of full-length obtained
from fermentations RDM 15 and RDM 16, 75% and 60%, respectively
(Figure 3b), this might have been caused by batch to batch variability,
and/or sample degradation during preparation for analysis. The differ-
ence was greater in the USP samples where there were proteases in
the supernatant, the DSP samples from the same fermentation showed
greater proportion of full-length P2-VP8-P[4] (72%) suggesting that
some proteolysis occurred during sample holding and preparation.
USP-DSP protocols were tested with a third independent batch
achieving 76% full-length P2-VP8-P[4] determined by intact MS analy-
sis with 81% total product recovery. In addition, an alternative
P[4] expression plasmid which failed to yield any full-length products
under standard BSM fermentation conditions (Section 2.2) was also
tested. Under the improved process, this produced 93% full-length
product (Figure 7b).
To serve as a platform process for the production of NRRV vac-
cine candidates, the USP-DSP must be capable of producing full-
length product from multiple virus serotypes. This USP-DSP protocol
was successfully tested with cells expressing different product con-
structs P2-VP8-P[4] and P2-VP8-P[8]. The MS results showed that
for both serotypes the greater proportion of product was full-length
being 72–93% for P[4] and 91% for P[8] (Figure 7b). Proving that it is
feasible to use this process as a platform for the production of differ-
ent NRRV antigens.
4 | CONCLUSION
Proteases can be problematic during the production of secreted heterol-
ogous proteins in P. pastoris.17,18 Here, we show that product truncation
can be addressed at a process level to improve the quality of NRRV anti-
gen. Fermentation process conditions have been improved to minimize
proteolysis using a novel acidic pH pulse strategy. This has resulted in a
fermentation harvest containing the majority of material as full-length, as
verified by intact mass spectrometry analysis. The use of RDM in fer-
mentations removes the need for a buffer exchange before DSP. A two-
step chromatography process (CIEX and AIEX) removed proteases
preventing further N-terminal proteolytic degradation of the NRRV anti-
gen. The resulting USP and DSP strategies are potentially compatible
F IGURE 7 Comparison of optimized and standard fed-batch
fermentation (USP) and purifications processes (DSP) for the
production of NRRV serotype P[4]. (a) pH traces for fermentations
in BSM or RDM carried out at constant pH or with a pH pulse, with
its corresponding proportion of full-length and truncated P[4] at
harvest and after CIEX and AIEX; DSP pre-treatment (C or D) and
number of chromatography steps see Figure 5b. (b) Intact mass
spectrometry from fermentation samples of NRRV P2-VP8-P[4] and
P2-VP8-P[8] serotypes
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with incorporation into an integrated production platform for manufac-
ture of clinical grade NRRV based vaccine on multiple serotypes.
For future studies, the identification of the specific proteases
involved will help in the more rapid design and implementation of com-
bined USP-DSP protocols for other secreted products in P. pastoris.
Although the two-step chromatography used reduces HCP and nucleic
acid levels to within specified tolerances, it is possible that removal of the
small amounts of residual product related impurities would require inclu-
sion of an additional step if this proves necessary for clinical grade
vaccine.
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